The Best At-Home CRP Test Is a Mail-In hs-CRP

If you want usable CRP data at home, order a high-sensitivity C-reactive protein (hs-CRP) test that ships you a collection device and routes the sample to a CLIA-certified lab running an immunoturbidimetric or immunonephelometric assay. Labcorp OnDemand and Quest’s consumer arm both do this, at roughly $50 to $70. The rapid finger-prick strips that return a number in ten minutes are built for a different job: they resolve CRP in the 10 to 200 mg/L range to triage acute infection. They cannot reliably tell 0.4 mg/L from 2.5 mg/L, which is the only distinction that matters for a healthy person tracking chronic inflammation.

The rest of this piece explains why that difference is decisive, what to check before you buy, and how to analyze a series of CRP values so you are reading signal rather than the assay’s own scatter.

hs-CRP and conventional CRP are the same molecule, different assays

C-reactive protein is an acute-phase protein made by the liver. It rises within six hours of an inflammatory stimulus and can reach several hundred mg/L in serious bacterial infection. Standard CRP assays were designed for that range and typically report a lower limit around 3 to 5 mg/L, with everything below reported as “<5”.

High-sensitivity CRP is the same analyte measured with a latex-enhanced method that extends the working range downward. The Roche Tina-quant hs-CRP assay, for example, quantifies down to roughly 0.15 mg/L with analytical coefficients of variation under 5% across the low range. That resolution is what makes the AHA/CDC tertiles meaningful: below 1 mg/L, 1 to 3 mg/L, and above 3 mg/L. A test that floors at 5 mg/L collapses all three into one bucket.

So the first filter on any at-home product is simple. If the listing does not say “high-sensitivity” or “hs-CRP” and does not state a limit of quantitation below 1 mg/L, it is the wrong test for your purpose.

What the collection method costs you

At-home kits use one of three collection paths, and they are not interchangeable.

Mobile phlebotomy or a partner draw site gives you serum or plasma from a venous stick. This is the reference condition for every published hs-CRP cutpoint. If you can get it, take it.

Capillary microsampling devices press a lancet against the upper arm and collect 100 to 600 µL into a cartridge. Tasso-SST and Mitra volumetric absorptive tips are the common ones. Correlation with venous hs-CRP is generally good, but the bias is method-specific and the failure rate is real. Under-filled devices get rejected by the lab, and squeezing the site to make volume introduces interstitial fluid that dilutes the sample.

Dried blood spots on filter paper are the cheapest and the most fragile. Recovery depends on hematocrit, spot size, and punch location. Shipping through a hot vehicle also degrades some analytes. For CRP specifically DBS performs acceptably, but the added preanalytical variance eats into your ability to detect change.

Our recommendation: use a venous draw when you can, a volumetric capillary device when you cannot, and treat dried blood spots as a last resort.

Why rapid point-of-care strips fail the use case

Lateral-flow CRP readers and small benchtop analyzers are sound instruments within their design range. The problem is that their range starts where your interest ends. Many report a lower detection limit of 8 to 10 mg/L, and the ones that claim lower typically have imprecision of 15% or more near the bottom of the scale.

There is also the hook effect. In one-step immunoassays, very high antigen concentration can saturate both capture and detection antibodies and produce a falsely low reading. A well-designed device mitigates this, but a cheap strip at 300 mg/L may report something unremarkable. That failure mode is silent, which is the worst kind.

If your goal is to check whether an acute illness is bacterial-looking or to watch a known inflammatory flare, a rapid device is reasonable. Even then, CRP alone is a blunt instrument for that question. In acute COPD exacerbations, copeptin and procalcitonin carried more prognostic information than CRP did.¹

Interpreting a single value, and why you should not

CRP has large within-person biological variation. Published estimates of the intra-individual coefficient of variation cluster in the 30% to 60% range, far above the assay’s analytical CV of 3% to 5%. Combine them into a reference change value and the arithmetic is unforgiving. With CVi at 42% and CVa at 4%, a two-sided change at 95% confidence requires roughly a 115% difference between two measurements.

In plain terms: a move from 0.8 to 1.4 mg/L is noise. A move from 0.8 to 2.5 mg/L is probably real. Anyone selling you week-over-week CRP trends is selling you the variance.

The practical protocol is to measure twice, two weeks apart, with no acute illness in the preceding month. Take the average of the two, or the lower one if they disagree wildly. If either value exceeds 10 mg/L, the AHA/CDC guidance is to discard the result and repeat later, because that range usually reflects an acute process rather than baseline. Persistent values above 10 mg/L without an obvious cause belong in a clinician’s hands. A spreadsheet is not the place for them.

Analyzing a CRP series

CRP is strongly right-skewed, so log-transform before you do anything statistical. Work with log(crp_mg_L), report geometric means, and plot on a log axis. A linear trendline on raw CRP is dominated by a handful of high points.

A minimal schema per measurement:

date,crp_mg_L,assay,lod_mg_L,collection,fasted,illness_14d,sleep_h_7d,steps_7d
2026-03-04,0.62,roche_hs,0.15,venous,1,0,7.1,8420

Record the covariates at collection time, because the interesting analysis is conditional. Short and poor-quality sleep have been associated with higher CRP in large population cohorts.²³ Daily step count shows an inverse association with both CRP and IL-6.⁴ Measured physical fitness tracks inversely with CRP in young people independent of adiposity.⁵ These are population associations, and they tell you which columns are worth logging. They are not personal causal claims.

If you are fitting anything, use a mixed model or simple outlier-resistant regression on the log scale with at least eight to ten measurements spread over a year. Fewer points and you are describing noise. Also record socioeconomic and work-context changes if you have them, since employment transitions and social position both associate with inflammatory markers in longitudinal data.⁶⁷

When CRP is the wrong marker

CRP is a downstream product of interleukin-6 signaling, which means it lags and smooths whatever IL-6 is doing. In cancer cachexia, IL-6 was compared directly against CRP and other markers as a predictor of clinical outcome.⁸ In end-stage renal disease, albumin, CRP, IL-6, and fetuin-A each carried distinct prognostic information for malnutrition and mortality.⁹ Pairing hs-CRP with IL-6 and albumin gives you a more interpretable picture than CRP alone.

Cell-count ratios are cheap additions too. Neutrophil-to-lymphocyte ratio and mean platelet volume come free with any CBC and have been examined as inflammation markers in pediatric bronchiectasis exacerbations.¹⁰ Order the CBC alongside the hs-CRP rather than separately.

Questions people also ask

What is the best at-home CRP test? A mail-in high-sensitivity CRP from a CLIA lab, collected by venous draw if available or a volumetric capillary device otherwise. Confirm the reported limit of quantitation is below 1 mg/L before ordering.

Is a home hs-CRP test as accurate as one from a doctor’s office? The assay is identical, because the same lab runs it. The difference lives in collection. A clean venous draw shipped promptly is equivalent, while a poorly filled capillary device or a heat-exposed dried spot is not.

Do I need to fast before a CRP test? No. CRP is not meaningfully affected by a recent meal. Fast only if you are bundling it with lipids or glucose on the same draw.

How often should I test? Twice at baseline two weeks apart, then quarterly. Anything more frequent is dominated by within-person variation unless you are tracking a known acute process.

What does a CRP above 3 mg/L mean? It places you in the upper tertile of the population distribution used in cardiovascular risk research. It is not a diagnosis of anything, and interpretation in the context of your other results is a conversation for a clinician.

Footnotes

1. Daiana Stolz, Mirjam Christ-Crain, Nils G. Morgenthaler, et al. Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPD. Chest, 2007. https://doi.org/10.1378/chest.06-2336 ↩

2. Marta Jackowska, Meena Kumari, Andrew Steptoe. Sleep and biomarkers in the English Longitudinal Study of Ageing: Associations with C-reactive protein, fibrinogen, dehydroepiandrosterone sulfate and hemoglobin. Psychoneuroendocrinology, 2013. https://doi.org/10.1016/j.psyneuen.2012.12.015 ↩

3. Jennifer Beam Dowd, Noreen Goldman, Maxine Weinstein. Sleep Duration, Sleep Quality, and Biomarkers of Inflammation in a Taiwanese Population. Annals of Epidemiology, 2011. https://doi.org/10.1016/j.annepidem.2011.07.004 ↩

4. Marilyn L. Moy, Merilee Teylan, Nicole A. Weston, et al. Daily Step Count Is Associated With Plasma C-Reactive Protein and IL-6 in a US Cohort With COPD. Chest, 2014. https://doi.org/10.1378/chest.13-1052 ↩

5. Carmen R. Isasi, Richard J. Deckelbaum, Russell P. Tracy, et al. Physical Fitness and C-Reactive Protein Level in Children and Young Adults: The Columbia University BioMarkers Study. Pediatrics, 2003. https://doi.org/10.1542/peds.111.2.332 ↩

6. Peter Muennig, Nancy Sohler, Bisundev Mahato. Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: Evidence from NHANES. Preventive Medicine, 2007. https://doi.org/10.1016/j.ypmed.2007.04.005 ↩

7. Tarani Chandola, Nan Zhang. Re-employment, job quality, health and allostatic load biomarkers: prospective evidence from the UK Household Longitudinal Study. International Journal of Epidemiology, 2017. https://doi.org/10.1093/ije/dyx150 ↩

8. Celena Scheede-Bergdahl, Heather L. Watt, Barbara Trutschnigg, et al. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?. Clinical Nutrition, 2012. https://doi.org/10.1016/j.clnu.2011.07.010 ↩

9. Hirokazu Honda, Abdul Rashid Qureshi, Olof Heimbürger, et al. Serum Albumin, C-Reactive Protein, Interleukin 6, and Fetuin A as Predictors of Malnutrition, Cardiovascular Disease, and Mortality in Patients With ESRD. American Journal of Kidney Diseases, 2006. https://doi.org/10.1053/j.ajkd.2005.09.014 ↩

10. Hikmet T. Nacaroglu, Semiha Bahceci Erdem, Sait Karaman, et al. Can mean platelet volume and neutrophil-to-lymphocyte ratio be biomarkers of acute exacerbation of bronchiectasis in children?. Central European Journal of Immunology, 2017. https://doi.org/10.5114/ceji.2017.72808 ↩